Morin S F, Charlebois E D
AIDS Policy Research Center, University of California AIDS Research Institute, San Francisco, USA.
AIDS Public Policy J. 2000 Summer;15(2):65-74.
Advances in biomedical research have resulted in new standards for HIV treatment that involve earlier intervention with more complex combination antiretroviral therapy. This article examines the implications of these treatments for federally funded programs that provide HIV care and discusses mechanisms for making Medicaid and the AIDS Drug Assistance Program (ADAP) consistent with the treatment standards. The article provides a rationale for expanding access by expanding entitlement programs (Medicaid) rather than discretionary programs (ADAP). A potential legislative approach to Medicaid expansion is described. Cost projections suggest that this approach is feasible and would constitute a significant step toward increasing access to HIV care.
生物医学研究的进展带来了新的HIV治疗标准，其中包括更早进行更复杂的联合抗逆转录病毒治疗干预。本文探讨了这些治疗方法对联邦资助的HIV护理项目的影响，并讨论了使医疗补助计划（Medicaid）和艾滋病药物援助计划（ADAP）与治疗标准保持一致的机制。本文为通过扩大权利性项目（医疗补助计划）而非自由裁量项目（ADAP）来扩大获取途径提供了理论依据。文中描述了一种扩大医疗补助计划覆盖范围的潜在立法方法。成本预测表明，这种方法是可行的，并且将朝着增加HIV护理的可及性迈出重要一步。
